Demethylating Agent 5-Aza-2′-Deoxycytidine Enhances Susceptibility of Renal Cell Carcinoma to Paclitaxel

Urology

Volumn 69, Issue 5, 2007, Pages 1007-1012

  Shang, Donghao ^a   Ito, Noriyuki ^a   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5' AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CELL ANTIGEN; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DEMETHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME ANALYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CASPASES; DEOXYCYTIDINE; DRUG SYNERGISM; FLOW CYTOMETRY; FLUOROURACIL; HISTORY, ANCIENT; HUMANS; KIDNEY NEOPLASMS; PACLITAXEL; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 34247563821     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.02.026     Document Type: Article

References (29)

1. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30 (2003) 843-852
2. Lanigan B. Prognostic factors in renal cell carcinoma. Br J Urol 75 (1995) 565-571
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2006. CA Cancer J Clin 56 (2006) 106-130
4. Yu D.S., Chang S.Y., and Ma C.P. The expression of MDR-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol 82 (1998) 544-547
5. Hartmann J.T., and Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 19 (1999) 1541-1543
6. Atzpodien J., Lopez H.E., and Kirchner H. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alpha-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13 (1995) 497-501
7. Lissoni P., Barni S., Ardizzoia A., et al. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-α. Eur J Cancer 28 (1992) 92-96
8. Motzer R.J., Murphy B.A., Bacik J., et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18 (2000) 2972-2980
9. Bex A., Kerst M., Mallo H., et al. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 49 (2006) 76-81
10. Ravaud A., Audhuy B., Gomez F., et al. Subcutaneous interleukin-2, interferon α-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter Phase II trial. J Clin Oncol 16 (1998) 2728-2732
11. Atzpodien J., Kirchner H., Hanninen E., et al. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 29 (1993) 56-58
12. Chalitchagorn K., Shuangshoti S., Hourpai N., et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 23 (2004) 8841-8846
13. Morris M.R., Hesson L.B., Wagner K.J., et al. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 22 (2003) 6794-6801
14. Banks R.E., Tirukonda P., Taylor C., et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66 (2006) 2000-2011
15. Willemze R., Suciu S., Archimbaud E., et al. A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 11 suppl 1 (1997) S24-S27
16. Lubbert M., Daskalakis M., Kunzmann R., et al. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2′-deoxycytidine (decitabine). Leuk Res 28 (2004) 1267-1271
17. Momparler R.L., Bouffard D.Y., Momparler L.F., et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8 (1997) 358-368
18. Gomyo Y., Sasaki J., Branch C., et al. 5-Aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 23 (2004) 6779-6787
19. Kaminski R., Kozar K., Niderla J., et al. Demethylating agent 5-aza-2′-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. Oncol Rep 12 (2004) 509-516
20. Berenbaum M.C. A method for testing for synergy with any number of agents. J Infect Dis 137 (1978) 122-130
21. Hattori K., and Akaza H. New combination chemotherapy in urological cancers. Gan To Kagaku Ryoho 27 (2000) 382-387
22. Jones P.A. DNA methylation errors and cancer. Cancer Res 56 (1996) 2463-2467
23. Thibault A., Figg W.D., Bergan R.C., et al. A phase II study of 5-aza-2′-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumor 84 (1998) 87-89
24. Missiaglia E., Donadelli M., Palmieri M., et al. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signaling pathway. Oncogene 24 (2005) 199-211
25. Hurtubise A., and Momparler R.L. Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anticancer Drugs 15 (2004) 161-167
26. Kanda T., Tada M., Imazeki F., et al. 5-Aza-2′-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncol Rep 14 (2005) 975-979
27. Alleman W.G., Tabios R.L., Chandramouli G.V., et al. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. Clin Cancer Res 10 (2004) 7011-7021
28. Shi H., Wei S.H., Leu Y.W., et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res 63 (2003) 2164-2171
29. Zhu W.G., Hileman T., Ke Y., et al. 5-Aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 279 (2004) 15161-15166